• Takeda secures global rights to develop and commercialise soticlestat pharmaceutical-business-review
    March 09, 2021
    Takeda Pharmaceutical Company has entered into an exclusive agreement to secure global rights from Ovid Therapeutics to develop and commercialise the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic ...
PharmaSources Customer Service